Print

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA)

https://www.facingourrisk.org/research-clinical-trials/study/62/athena-rucaparib-and-nivolumab-for-maintenance-in-ovarian-cancer

Clinicaltrials.gov identifier:
NCT03522246 (https://clinicaltrials.gov/show/NCT03522246)


Study Contact Information:

The ATHENA study is open at many locations across the United States and around the world. For a full list of open sites, contact Clovis Oncology Clinical Trial Information Line at: 1-855-262-3040 (USA) or +1-303-625-5160 (ex-USA), or by email


About the Study

ATHENA is a study for women who are newly diagnosed with ovarian cancer. The goal of ATHENA is to look at whether giving maintenance therapy with different agents improves outcomes for women who have completed front-line treatment. 

UPDATE: THIS STUDY IS NO LONGER ENROLLING PATIENTS

Type of Study

ATHENA is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance treatment following response to front-line treatment in newly diagnosed ovarian cancer patients. Response to treatment will be evaluated based on homologous recombination repair gene mutation status of tumor samples.

What the Study Entails

Study Sites

The ATHENA study is open at many locations across the United States and around the world. For a full list of open sites, contact Clovis Oncology Clinical Trial Information Line at: 1-855-262-3040 (USA) or +1-303-625-5160 (ex-USA), or by email.

 


This Study is Open To:

UPDATE: THIS STUDY IS NO LONGER ENROLLING PATIENTS

This Study is Not Open To:


About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.